Harnessing Artifical Intelligence in Bladder Cancer: Digital Tools for Enhanced Diagnosis and Treatment – David McConkey

David McConkey discusses the application of artificial intelligence (AI) in bladder cancer research, focusing on AI pathology. He outlines ongoing collaborations between cooperative groups and industry partners to develop and validate AI tools for cancer diagnosis and treatment prediction. Dr. McConkey emphasizes the importance of open access data, quality control, and rigorous validation in AI…

Read the full article here

Source: www.urotoday.com

Categories: General News, General Medicine News

Tags: ArtificalIntelligence,BladderCancer,AI

Tweets with this article

UroToday.com

Harnessing #ArtificalIntelligence in #BladderCancer. @djmcconkey and @UroDocAsh discuss #AI and its role in diagnosis and treatment, emphasizing collaboration, open data, and validation, and AI's potential to complement or replace traditional pathology > https://t.co/GUe88n9Mhk https://t.co/HhmOPP49i8

Related Articles

Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024

Kim, Sindher, Huffaker spoke with HCPLive about some of the year’s most important developments in the food allergy space, namely the approvals of omalizumab and…

MD Mag December 21, 2024

AI-Powered Prostate Cancer Grading Predicts Active Surveillance Outcomes – Cornelia Ding

Andrea Miyahira interviews Cornelia (Chien-Kuang) Ding about her study on predicting prostate cancer grade reclassification using a deep learning-based grading algorithm. Dr. Ding discusses their…

UroToday.com December 20, 2024

stats

Published: 12/19.2024

CDC December 20, 2024

Advancing Female Bladder Cancer Care: Insights from AUA’s First Specialized Course – Armine Smith

Ashish Kamat introduces Armine Smith to discuss the intricacies of treating female bladder cancer, emphasizing organ and sexual function preservation during radical cystectomy. Highlighting a…

UroToday.com December 20, 2024

MAST Trial Finds Metformin Ineffective in Preventing Prostate Cancer Progression – Neil Fleshner

Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance…

UroToday.com December 20, 2024

Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

pharmalot December 20, 2024

Exploring Genetic Counseling in Veterans with Advanced Prostate Cancer – Daniel Kwon

Daniel Kwon presents a study on genetic counseling for Veterans with advanced prostate cancer. This mixed-methods research combines in-depth qualitative interviews and quantitative surveys to…

UroToday.com December 20, 2024

Pharmalittle: We’re reading about the end of a Lilly drug shortage, a Novo obesity trial disappointment, and more

Novo Nordisk’s next-generation obesity candidate led to substantial weight loss in a pivotal study but fell short of expectations

pharmalot December 20, 2024

MedCity FemFwd: How Celmatix is Using ARPA-H’s Sprint for Women’s Health Funding – MedCity News

In this episode, we’re joined by Dr. Piraye Yurttas Beim, founder and CEO of Celmatix, a women’s health biotech company. She discusses the funding the…

MedCity News December 20, 2024

Treatment Decision Making in mCRPC: The Urologist and Patient “What the Patient Needs to Know” About His Disease and Treatment Options? – Brenda Martone

Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…

UroToday.com December 20, 2024